Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



Chrysin protects against kidney tissue damage caused by pemetrexed used in cancer treatment

Kevser TANBEK,Evren KOSE.




Abstract

Pemetrexed (PMTX) is a multi-targeted, anticancer, antifolate agent that exerts its effect by disrupting the folate-dependent metabolic processes underlying cell proliferation. Kidney toxicity is a common side effect of anticancer agents. Chrysin (Chr) is a powerful antioxidant compound abundant in plant extracts, honey, and bee propolis. The aim of this study is to investigate the effect of the combined use of chrysin, a natural flavonoid, against the possible harmful effects of PMTX on kidney tissue.
50 male Wistar albino rats were divided into five groups: Control, Sham, PMTX, Chr, PMTX+Chr. Sham (1ml corn oil/day), CH (50mg/kg/day) by oral gavage, PMTX (1mg/kg/week) by i.p., PMTX+CH (PMTX;1mg/kg/week, CH;50mg/kg/day) were given at the same time every day. At the end of 4 weeks at the end of the study, blood and kidney tissues were collected. The malondialdehyde (MDA), superoxide dismutase (SOD) activities, and total antioxidant (TAS), total oxidant status (TOS), OSI also were measured. Blood-urea-nitrogen (BUN) and creatinine (Cr) analyzed by ELISA.
Indicators of oxidative stress, MDA was elevated and antioxidant activity was reduced in the PMTX group compared to control and Sham (p

Key words: Pemetrexed, Chrysin, Kidney, Oxidative Stress, Rat






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.